Restricted accessResearch articleFirst published online 2006-10
Paclitaxel Delivered to Adventitia Attenuates Neointima Formation without Compromising Re-Endothelialization after Angioplasty in a Porcine Restenosis Model
To investigate the effect of paclitaxel delivered into the adventitia of pig femoral arteries on neointima formation and hyperplasia as well as re-endothelialization.
Methods:
Paclitaxel or vehicle was delivered into the adventitia of pig femoral arteries using a needle injection catheter following balloon overstretch. Arteries were then serially examined by angiography, Evan's blue staining, morphometry, and immunohistochemistry for up to 12 weeks.
Results:
Local adventitial delivery of paclitaxel significantly attenuated neointima formation. The area of neointima (0.41±0.17 versus 2.75±0.81 mm2, p<0.01), the ratio of intima to media (0.12±0.05 versus 0.86±0.35, p<0.05), and the degree of stenosis (12.80%±3.13% versus 47.06%±7.25%, p<0.01) were significantly lower in the paclitaxel-treated group compared to controls. Furthermore, cell proliferation was significantly diminished following adventitial delivery of paclitaxel from day 3 to 21 compared to controls. Complete reendothelialization was observed 3 weeks after intervention in both groups of arteries treated with paclitaxel or vehicle alone.
Conclusion:
Paclitaxel delivered into the adventitia of pig femoral arteries effectively attenuates neointima formation after angioplasty without compromising re-endothelialization. Adventitial drug delivery may therefore be an alternative to drug-eluting stents for the prevention of restenosis.
MoriceMCSerruysPWSousaJE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002; 346: 1773–1780.
3.
MosesJWMehranRNikolskyE. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: Analysis from the TAXUS-IV trial. J Am Coll Cardiol.2005; 45: 1165–1171.
4.
MosesJWLeonMBPopmaJJ. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003; 349: 1315–1323.
5.
ParkSJShimWHHoDS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med.2003; 348: 1537–1545.
6.
ValgimigliMvan MieghemCAOngAT. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: Insights from the Rapamycin-Eluting and Taxus Stent Evaluated at Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation. 2005; 111: 1383–1389.
7.
HuehnsTYGonschiorPHoflingB. Adventitia as a target for intravascular local drug delivery. Heart. 1996; 75: 537–538.
8.
ScottNACipollaGDRossCE. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation. 1996; 93: 2178–2187.
9.
ShiYO'BrienJEFardA. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996; 94: 1655–1664.
10.
NikolSHuehnsTYKrauszE. Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther.1999; 6: 737–748.
11.
PelisekJKuehnlARollandPH. Functional analysis of genomic DNA, cDNA, and nucleotide sequence of the mature C-type natriuretic peptide gene in vascular cells. Arterioscler Thromb Vasc Biol.2004; 24: 1646–1651.
12.
NikolSEngelmannMGPelisekJ. Local perivascular application of low amounts of a plasmid encoding for vascular endothelial growth factor (VEGF165) is efficient for therapeutic angiogenesis in pigs. Acta Physiol Scand.2002; 176: 151–159.
13.
SollottSJChengLPaulyRR. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995; 95: 1869–1876.
14.
AxelDIKunertWGoggelmannC. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96: 636–645.
15.
DrachmanDEEdelmanERSeifertP. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol.2000; 36: 2325–2332.
16.
HeldmanAWChengLJenkinsGM. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001; 103: 2289–2295.
17.
ColomboADrzewieckiJBanningA. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003; 108: 788–794.
JordanMATosoRJThrowerD. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A.1993; 90: 9552–9556.
20.
TanabeKSerruysPWGrubeE. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003; 107: 559–564.
21.
IkenoFLyonsJKanedaH. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv.2004; 63: 222–230.
22.
CellettiFLWaughJMAmabilePG. Inhibition of vascular endothelial growth factor-mediated neointima progression with angio-statin or paclitaxel. J Vasc Interv Radiol.2002; 13: 703–707.
23.
MasakiTRathiRZentnerG. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int.2004; 66: 2061–2069.
24.
OngATMcFaddenEPRegarE. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol.2005; 45: 2088–2092.
25.
LiistroFColomboA. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. 2001; 86: 262–264.
26.
PelisekJArmeanuSNikolS. Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors. Cell Prolif. 2001; 34: 305–320.
27.
BautersCIsnerJM. The biology of restenosis. Prog Cardiovasc Dis.1997; 40: 107–116.
28.
LiGChenSJOparilS. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000; 101: 1362–1365.
29.
HuYZhangZTorsneyE. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest. 2004; 113: 1258–1265.
30.
FukudaDShimadaKTanakaA. Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol.2004; 43: 18–23.
31.
SataMSaiuraAKunisatoA. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med.2002; 8: 403–409.
32.
HouDRogersPIToleikisPM. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation. 2000; 102: 1575–1581.
HutterRSauterBVReisED. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. Circulation. 2003; 107: 1658–1663.
35.
WalterDHCejnaMDiaz-SandovalL. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: An alternative strategy for inhibition of restenosis. Circulation. 2004; 110: 36–45.
36.
VirmaniRFarbAKolodgieFD. Histopathologic alterations after endovascular radiation and antiproliferative stents: Similarities and differences. Herz. 2002; 27: 1–6.
37.
LiuzzoJPAmbroseJACoppolaJT. Sirolimus-and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol.2005; 17: 497–502.
38.
SousaJESerruysPWCostaMA. New frontiers in cardiology: Drug-eluting stents: Part II. Circulation. 2003; 107: 2383–2389.
39.
VirmaniRGuagliumiGFarbA. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?Circulation. 2004; 109: 701–705.
40.
van der GiessenWJLincoffAMSchwartzRS. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690–1697.
41.
WoodS. Polymer problems or doctor error? Deployment glitches with Taxus stent spur disquiet and reassurances. theheart.org. [HeartWire News]; April 29, 2004. Accessed at http://www.theheart.org/article/134247.do on July 20, 2006.
42.
WalshKSmithRCKimHS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res.2000; 87: 184–188.
43.
BauriedelGSchluckebierSHutterR. Apoptosis in restenosis versus stable-angina atherosclerosis: Implications for the pathogenesis of restenosis. Arterioscler Thromb Vasc Biol.1998; 18: 1132–1139.
44.
LuoZSataMNguyenT. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999; 99: 1776–1779.
45.
ParryTJBrosiusRThyagarajanR. Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol.2005; 524: 19–29.
46.
ArmeanuSPelisekJKrauszE. Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther.2000; 1: 366–375.
47.
HuehnsTYKrauszEMrochenS. Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atherosclerosis. 1999; 144: 135–150.
48.
PelsKDeinerCCouplandSE. Effect of adventitial VEGF(165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res.2003; 60: 664–672.
49.
MikawaTGourdieRG. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev Biol.1996; 174: 221–232.
50.
ShimizuMPelisekJNikolS. Vasculogenesis and angiogenesis depend on the developmental origin in the arterial tree. Curr Med Chem.2002; 9: 1619–1630.
51.
PatelSShiYNiculescuR. Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation. 2000; 101: 524–532.
